Kumar Ravindra 4
4 · ACCELERON PHARMA INC · Filed Sep 29, 2017
Insider Transaction Report
Form 4
Kumar Ravindra
VP & Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2017-09-28$5.28/sh+6,761$35,698→ 96,975 total - Exercise/Conversion
Option to Purchase Common Stock
2017-09-28−6,761→ 0 totalExercise: $5.28Exp: 2022-06-07→ Common Stock (6,761 underlying)
Footnotes (1)
- [F1]The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.